Identification of novel synthetic lethal interactions in small cell lung cancer with the proteasome inhibitor carfilzomib

被引：0
|
作者：
Masto, Vincent B. [1 ]
Lerner, Alana G. [1 ]
Arastu-Kapur, Shirin [1 ]
机构：
[1] Onyx Pharmaceut, San Francisco, CA USA
来源：
CANCER RESEARCH | 2015年 / 75卷
关键词：
D O I：
10.1158/1538-7445.AM2015-1735
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1735
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Identification of novel KRAS-synthetic lethal targets for treatment of KRAS-dependent Non-Small Cell Lung Cancer
    Kostyrko, Kaja
    Simpson, David
    Broyde, Joshua
    Kelly, Marcus
    Califano, Andrea
    Honig, Barry
    Jackson, Peter
    Sweet-Cordero, Alejandro
    MOLECULAR CANCER THERAPEUTICS, 2017, 16 (10)
  • [2] Novel Use of the Proteasome Inhibitor Carfilzomib for Antibody Mediated Rejection After Lung Transplantation
    Ensor, C.
    Zeevi, A.
    Morrell, M.
    Yousem, S.
    D'Cunha, J.
    Pilewski, J.
    Bermudez, C.
    Shullo, M.
    Teuteberg, J.
    McDyer, J.
    TRANSPLANTATION, 2014, 98 : 806 - 807
  • [3] Carfilzomib: a novel second-generation proteasome inhibitor
    Khan, Meaghan L.
    Stewart, A. Keith
    FUTURE ONCOLOGY, 2011, 7 (05) : 607 - 612
  • [4] Novel Use of the Proteasome Inhibitor Carfilzomib for Antibody Mediated Rejection After Lung Transplantation.
    Ensor, C.
    Zeevi, A.
    Morrell, M.
    Yousem, S.
    D'Cunha, J.
    Pilewski, J.
    Bermudez, C.
    Shullo, M.
    Teuteberg, J.
    McDyer, J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 806 - 807
  • [5] Identification of novel combinatorial synthetic lethal vulnerabilities in KRAS-driven lung cancer
    Kostyrko, Kaja
    Kelly, Marcus R.
    Han, Kyuho
    Jeng, Edwin E.
    Morgens, David W.
    Bassik, Michael C.
    Jackson, Peter K.
    Sweet-Cordero, Alejandro
    CANCER RESEARCH, 2018, 78 (13)
  • [6] First Experience With the Novel Proteasome Inhibitor Carfilzomib for Antibody Mediated Rejection After Lung Transplantation
    Ensor, C. R.
    Zeevi, A.
    Morrell, M. R.
    Yousem, S. A.
    D'Cunha, J.
    Pilewski, J. M.
    Bermudez, C.
    Shullo, M. A.
    Teuteberg, J. J.
    McDyer, J. F.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2014, 33 (04): : S114 - S114
  • [7] Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
    Taromi, Sanaz
    Lewens, Florentine
    Arsenic, Ruza
    Sedding, Dagmar
    Saenger, Jorg
    Kunze, Almut
    Moebs, Markus
    Benecke, Joana
    Freitag, Helma
    Christen, Friederike
    Kaemmerer, Daniel
    Lupp, Amelie
    Heilmann, Mareike
    Lammert, Hedwig
    Schneider, Claus-Peter
    Richter, Karen
    Hummel, Michael
    Siegmund, Britta
    Burger, Meike
    Briest, Franziska
    Grabowski, Patricia
    ONCOTARGET, 2017, 8 (57) : 97061 - 97078
  • [8] Identification of synthetic lethal interactions with the BRAF oncogene in colorectal cancer
    Vecchione, Loredana
    Gambino, Valentina
    d'Ario, Giovanni
    Tian, Sun
    Simon, Iris
    Popovici, Vlad Calin
    Delorenzi, Mauro
    Bernards, Rene
    Tejpar, Sabine
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [9] Identification of a novel HASPIN inhibitor and the synthetic lethal partner by computational analysis
    Kwon, Eun-Ji
    Mashelkar, Karishma
    Lee, Hyuk Woo
    Shin, Yoon-Ze
    Jeong, Lak Shin
    Cha, Hyuk-Jin
    CANCER RESEARCH, 2022, 82 (12)
  • [10] Comparative genomics as a tool for the identification of novel Kras synthetic lethal interactions
    Sweet-Cordero, Alejandro
    CANCER RESEARCH, 2011, 71
12345